Publications by authors named "Johan Lund"

Claim this Profile
E
European Expert Panel Consensus on Outpatient Administration of Teclistamab and Talquetamab in Patients With Multiple Myeloma: Feasibility, Key Considerations, and Future Directions.
Thomas Lund, Cyrus Khandanpour, Sébastien Anguille, Jens Kisro, Maria Theresa Krauth, Johan Lund

Eur J Haematol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
T cell phenotype and clonality changes in myeloma patients with short overall survival.
Alenka Djarmila Behsen, Esten Nymoen Vandsemb, Tobias Schmidt Slørdahl, Karen Dybkær, Maja Zimmer Jakobsen, Johan Lund

JCI Insight· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Minimal residual disease status is the prognostic determinant following high-dose treatment for patients with multiple myeloma.
Hareth Nahi, Gabriel Afram, Katarina Uttervall, Sandra Lockmer, Love Tätting, Johan Lund

Cancer Med· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of newly diagnosed extramedullary myeloma on outcome after first autograft followed by maintenance: A CMWP-EBMT study.
Nico Gagelmann, Dirk-Jan Eikema, Linda Koster, Tanja Netelenbos, Andrew McDonald, Johan Lund

Eur J Haematol· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Challenges in αCD38-chimeric antigen receptor (CAR)-expressing natural killer (NK) cell-based immunotherapy in multiple myeloma: Harnessing the CD38dim phenotype of cytokine-stimulated NK cells as a strategy to prevent fratricide.
Maria Karvouni, Marcos Vidal-Manrique, Katharina H Susek, Alamdar Hussain, Mari Gilljam, Johan Lund, Andreas Lundqvist

Cytotherapy· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Generation of NK cells with chimeric-switch receptors to overcome PD1-mediated inhibition in cancer immunotherapy.
Katharina H Susek, Ysabel A Schwietzer, Maria Karvouni, Mari Gilljam, Marton Keszei, Johan Lund, Andreas Lundqvist

Cancer Immunol Immunother· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response to Caravita di Toritto and Rago.
Roza Chaireti, Katarina Uttervall, Vincent Luong, Johan Lund, Muhammad Kashif

Eur J Haematol· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Accuracy of fatal occupational injury registration in a high-income country: A comparison of two-source capture-recapture estimates with the number of cases identified in four register systems in Norway, 2000-2003.
Finn Gjertsen, Johan Lund, Ebba Wergeland

Glob Epidemiol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Conditioning with melphalan 200 mg/m and subsequent ASCT improves progression-free and overall survival in elderly myeloma patients compared to standard of care.
Gabriel Afram, Roza Chaireti, Katarina Uttervall, Vincent Luong, Johan Lund

Eur J Haematol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Regional differences in treatment and outcome for myeloma patients in Sweden: A population based Swedish myeloma register study.
Göran Wålinder, Anna Genell, Gunnar Juliusson, Ronald Svensson, Antonio Izarra Santamaria, Johan Lund

Cancer Rep (Hoboken)· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[The Lighthouse Project – a new national injury registry].
Johan Lund, Anne Mette Bjerkan, Marianne Dahlhaug, Inger Dahlstrøm, Marte Lillehagen Garnes

Tidsskr Nor Laegeforen· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Injury severity and increased socioeconomic differences: A population-based cohort study.
Christian Madsen, Belinda J Gabbe, Kristin Holvik, Kari Alver, Else Karin Grøholt, Johan Lund

Injury· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Autologous NK cells as consolidation therapy following stem cell transplantation in multiple myeloma.
Hareth Nahi, Michael Chrobok, Stephan Meinke, Charlotte Gran, Nicole Marquardt, Johan Lund

Cell Rep Med· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antibody response to COVID-19 mRNA vaccine (Comirnaty) in myeloma patients treated with high-dose melphalan and/or immunotherapy.
Sandra Lockmer, Katarina Uttervall, Muhammad Kashif, Carina Svärd, Katarina Malmsten, Johan Lund

Am J Hematol· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IgD Subtype But Not IgM or Non-Secretory Is a Prognostic Marker for Poor Survival Following Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. Results From the EBMT CALM (Collaboration to Collect Autologous Transplant Outcomes in Lymphomas and Myeloma) Study.
Sarah Lawless, Giulia Sbianchi, Curly Morris, Simona Iacobelli, Paul Bosman, Johan Lund

Clin Lymphoma Myeloma Leuk· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low dose venetoclax as a single agent treatment of plasma cell malignancies harboring t(11;14).
Hareth Nahi, Muhammad Kashif, Monika Klimkowska, Maria Karvouni, Ann Wallblom, Johan Lund

Am J Hematol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improved survival in multiple Myeloma patients undergoing autologous stem cell transplantation is entirely in the standard cytogenetic risk groups.
Gabriel Afram, Katharina Helene Susek, Katarina Uttervall, Johanna Dehlsen Wersäll, Arnika Kathleen Wagner, Johan Lund

Eur J Haematol· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dynamic follow-up of smoldering multiple myeloma identifies a subset of patients at high risk of progression.
Charlotte Gran, Vincent Luong, Johanna B Bruchfeld, Johan Liwing, Gabriel Afram, Johan Lund

Am J Hematol· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incidence of injuries in Norway: linking primary and secondary care data.
Eyvind Ohm, Kristin Holvik, Christian Madsen, Kari Alver, Johan Lund

Scand J Public Health· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Infectious complications and NK cell depletion following daratumumab treatment of Multiple Myeloma.
Hareth Nahi, Michael Chrobok, Charlotte Gran, Johan Lund, Astrid Gruber

PLoS One· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Upfront bortezomib, lenalidomide, and dexamethasone compared to bortezomib, cyclophosphamide, and dexamethasone in multiple myeloma.
Katarina Uttervall, Johanna Borg Bruchfeld, Charlotte Gran, Göran Wålinder, Robert Månsson, Johan Lund

Eur J Haematol· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Pilot, Exploratory, Randomized, Phase II Safety Study Evaluating Tumor Cell Mobilization and Apheresis Product Contamination in Patients Treated with Granulocyte Colony-Stimulating Factor Alone or Plus Plerixafor.
Hareth Nahi, Marina Celanovic, Qianying Liu, Johan Lund, Valdas Peceliunas

Biol Blood Marrow Transplant· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second-line lenalidomide + dexamethasone induction in multiple myeloma.
Johan Lund, Astrid Gruber, Birgitta Lauri, Adil Doganay Duru, Cecilie Blimark, Ulf Frølund

Cancer Med· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacogenetic study of the impact of ABCB1 single-nucleotide polymorphisms on lenalidomide treatment outcomes in patients with multiple myeloma: results from a phase IV observational study and subsequent phase II clinical trial.
Ingrid Jakobsen Falk, Johan Lund, Henrik Gréen, Astrid Gruber, Evren Alici

Cancer Chemother Pharmacol· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Re-challenging with anti-CD38 monotherapy in triple-refractory multiple myeloma patients is a feasible and safe approach.
Evren Alici, Michael Chrobok, Johan Lund, Tahamtan Ahmadi, Imran Khan

Br J Haematol· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis